Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

302.92 +8.97 (+3.05%)

Streaming Delayed Price Updated: 3:20 PM EDT, Mar 16, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	146,751
Open	301.46
Bid (Size)	301.14 (100)
Ask (Size)	303.26 (200)
Prev. Close	293.95
Today's Range	301.29 - 311.00
52wk Range	26.70 - 356.00
Shares Outstanding	44,712,538
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗

March 15, 2026

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

Via The Motley Fool

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗

March 13, 2026

Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.

Via The Motley Fool

Performance

YTD	+5.8%	+5.8%
1 Month	-4.5%	-4.5%
3 Month	+9.6%	+9.6%
6 Month	+648.9%	+648.9%
1 Year	+678.1%	+678.1%

More News

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗

March 13, 2026

Via The Motley Fool

Praxis Precision Medicines (NASDAQ:PRAX) Reports Q4 2025 Results Amid Key Regulatory Milestones ↗

February 19, 2026

Via Chartmill

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline ↗

March 13, 2026

Via The Motley Fool

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗

March 13, 2026

Via The Motley Fool

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗

March 13, 2026

Via The Motley Fool

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗

March 13, 2026

Via The Motley Fool

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 04, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Via The Motley Fool

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Via The Motley Fool

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Via The Motley Fool

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Via The Motley Fool

Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock ↗

February 20, 2026

Via Stocktwits

Praxis Medicines Q4 2025 Earnings Call Transcript ↗

February 19, 2026

Via The Motley Fool

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

February 19, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Via Stocktwits

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Via The Motley Fool

Soleus Adds a Significant Number of Celcuity Shares ↗

February 13, 2026

Via The Motley Fool

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

February 09, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 04, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

Via MarketMinute

Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

January 13, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

January 12, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Praxis Precision Medicines, Inc. - Common Stock publicly traded?

Yes, Praxis Precision Medicines, Inc. - Common Stock is publicly traded.

What exchange does Praxis Precision Medicines, Inc. - Common Stock trade on?

Praxis Precision Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Praxis Precision Medicines, Inc. - Common Stock?

The ticker symbol for Praxis Precision Medicines, Inc. - Common Stock is PRAX on the Nasdaq Stock Market

What is the current price of Praxis Precision Medicines, Inc. - Common Stock?

The current price of Praxis Precision Medicines, Inc. - Common Stock is 302.92

When was Praxis Precision Medicines, Inc. - Common Stock last traded?

The last trade of Praxis Precision Medicines, Inc. - Common Stock was at 03/16/26 03:20 PM ET

What is the market capitalization of Praxis Precision Medicines, Inc. - Common Stock?

The market capitalization of Praxis Precision Medicines, Inc. - Common Stock is 13.54B

How many shares of Praxis Precision Medicines, Inc. - Common Stock are outstanding?

Praxis Precision Medicines, Inc. - Common Stock has 14B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.